#USA #Los Angeles #Schall Law Firm #Securities Fraud #Ultragenyx

The Schall Law Firm, a prominent player in shareholder rights litigation, has issued a reminder for investors regarding a significant class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). This case primarily addresses alleged violations of the Securities Exchange Act of 1934, specifically under Section 10(b) and 20(a), as well as Rule 10b-5, which is enforced by the U.S. Securities and Exchange Commission. Investors who acquired Ultragenyx's securities between August 3, 2023 and December 26, 2025, are strongly urged to take action promptly, as the deadline for participation is April 6, 2026. Those who suffered financial losses related to their investments in Ultragenyx are encouraged to reach out to the Schall Law Firm to explore their rights at no initial cost. Interested shareholders can contact Brian Schall at the firm's Los Angeles office, or visit their website for further information on how to proceed. Reports indicate that Ultragenyx allegedly disseminated false and misleading information regarding its understanding of the impact its drug candidate had on patients suffering from Osteogenesis Imperfecta (OI). The crux of the complaint indicates that the company's misrepresentations were unveiled during the Phase III ORBIT study, where results indicated a failure to realize a statistically significant reduction in the annualized fracture rate (AFR) in the clinical trials. This failure reflects continuous misrepresentations throughout the class period, leading to substantial losses for investors upon the emergence of these facts. The implications for investors are significant; they might recover lost funds if they choose to defend their rights in this forthcoming legal action. Investors should be aware that the class in the lawsuit has not yet obtained certification, meaning that opting out of participation could leave them unrepresented. The Schall Law Firm actively represents clients on a global scale, focusing on securities class actions and the protection of shareholder rights. With their experience in handling such matters, investors can trust in their expertise to navigate the complexities of this case and advocate for appropriate remedies. As this class action unfolds, it represents an opportunity for investors to unite and confront any corporate malfeasance effectively. By taking joint action, aggrieved investors can hold Ultragenyx accountable for its actions and possibly recoup some of their financial losses. For those considering joining the lawsuit or seeking more information about their potential claims, contacting the Schall Law Firm provides the first step toward legal recourse. Investors are reminded to remain vigilant and proactive in defending their rights, particularly in such an uncertain financial landscape. Actions taken now could hold significant implications for their future financial wellbeing, as the outcome of this case could sway investor confidence and the broader market perceptions surrounding Ultragenyx Pharmaceutical.